Are you looking for new investment ideas for your ISA? Come to the Shares and AJ Bell Investor Evening in London on Wednesday 7 March 2018. Directors from Allergy Therapeutics (AGY), Bluejay Mining (JAY), Healthperm (HPR) and Mercia Technologies (MERC) will present their plans for 2018 and you will also have the opportunity to talk directly to these directors and put forward your questions.
Allergy Therapeutics (AGY) - Allergy Therapeutics is a Europe-based specialty pharmaceutical company focused upon the diagnosis and treatment of allergy. Allergy Therapeutics has an existing sales base of approximately £40 million per year, an MHRA-approved manufacturing capability as well as an established sales and marketing infrastructure in several major European markets.
Bluejay Mining (JAY) - Bluejay Mining is primarily focused on advancing the Dundas ilmenite project in Greenland into production in 2018. Dundas is the highest-grade mineral sand ilmenite project globally, and with just 17% of the raised beach area having been assessed the true scale of this deposit is only just emerging.
Healthperm (HPR) - Healthperm is a healthcare recruitment business, which has been established to address the significant shortfalls in healthcare professionals in the UK and the UAE. The objective is to become a trusted provider of permanent experienced nurses and other healthcare professionals initially from the Philippines into the UK and the UAE.
Mercia Technologies (MERC) - Mercia is a national investment group focused on the funding and scaling of innovative technology businesses with high growth potential from the UK regions. Mercia benefits from 19 university partnerships and offices across the Midlands, the North of England and Scotland providing it with access to high quality, regional deal flow.
Who Should Attend
The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy.